Amuvatinib

Drug Overview

The medication known as amuvatinib (also referred to by its laboratory code MP-470) is an advanced, orally available “smart drug” designed to overcome the primary challenge in modern oncology: drug resistance. It is a synthetic molecule classified as a multi-targeted tyrosine kinase inhibitor (TKI). Unlike many targeted therapies that only block one pathway, amuvatinib is engineered to block several “escape routes” that cancer cells use to survive and continue growing.

In the clinical landscape, amuvatinib is recognized as a “DNA repair suppressor.” Its unique chemical structure allows it to interfere with the way cancer cells fix themselves after being damaged by chemotherapy or radiation. By disabling these repair mechanisms, amuvatinib acts as a “sensitizer,” making standard treatments significantly more lethal to the tumor.

• Generic Name: Amuvatinib.
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: Multi-targeted Tyrosine Kinase Inhibitor (TKI) / DNA Repair Inhibitor.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of early 2026, it is in Phase II clinical trials and has received Orphan Drug Designation for specific rare cancers, but is not yet approved for general clinical use.

What Is It and How Does It Work? (Mechanism of Action)

Amuvatinib functions as a molecular “triple-threat.” To understand its action at the molecular level, we must look at the three specific proteins it targets.

The Triple-Inhibitor Strategy

Amuvatinib is designed to bind to the “ATP-binding pockets” of three critical enzymes: c-Kit, PDGFR$\alpha$, and AXL.

Molecular Level Mechanisms

1. Blocking Growth Signals (c-Kit & PDGFR$\alpha$): These receptors act like antennas on the cell surface. When they receive a signal, they tell the cancer cell to divide. Amuvatinib “plugs” these antennas, cutting off the growth instructions at the source.
2. Inhibiting AXL (The Resistance Marker): AXL is a protein that cancer cells often turn on to become resistant to other treatments. By inhibiting AXL, amuvatinib prevents the cancer from “learning” how to hide from chemotherapy.
3. Suppression of RAD51: This is the drug’s most unique feature. RAD51 is a protein essential for “Homologous Recombination”—a high-fidelity way that cells repair double-strand breaks in their DNA. Amuvatinib lowers the levels of RAD51.
4. Synergistic Lethality: When a patient receives chemotherapy (which breaks DNA) along with amuvatinib, the cancer cell tries to use RAD51 to fix the damage. Because amuvatinib has suppressed RAD51, the cancer cell cannot repair itself and is forced into apoptosis (programmed cell death).

FDA-Approved Clinical Indications

Amuvatinib is an investigational agent and is currently available only through enrollment in clinical trials for the following high-priority areas:

Oncological Uses (In Clinical Trials):

• Small Cell Lung Cancer (SCLC): Used in combination with chemotherapy to prevent early relapse.
• Gastrointestinal Stromal Tumors (GIST): Investigated for patients who have become resistant to standard drugs like Imatinib.
• Neuroendocrine Tumors: Testing its ability to slow growth in aggressive hormonal cancers.
• Advanced Solid Tumors: Used in “combination trials” with drugs like paclitaxel or carboplatin.

Non-oncological Uses:

• There are currently no non-oncological uses for amuvatinib.

Dosage and Administration Protocols

In clinical trial settings, amuvatinib is taken as an oral capsule. The dosing is designed to maintain a “steady-state” concentration in the blood to keep the DNA repair pathways permanently suppressed.

Clinical Efficacy and Research Results

Recent clinical data (2020–2026) has focused on amuvatinib’s role as a “potentiator”—a drug that makes other drugs work better.

• Combination Success in SCLC: In Phase Ib/II trials, the combination of amuvatinib with etoposide and cisplatin showed a Disease Control Rate (DCR) of approximately 68% in patients with extensive-stage small cell lung cancer.
• Overcoming GIST Resistance: Research indicates that amuvatinib can successfully bind to mutated versions of c-Kit that other drugs cannot reach, leading to “Stable Disease” in nearly 30% of patients who had failed three prior lines of therapy.
• RAD51 Reduction: Molecular studies on patient biopsies confirm that amuvatinib reduces RAD51 protein levels by over 50% within the first 7 days of treatment, proving the “DNA-repair suppression” theory works in humans.

Safety Profile and Side Effects

Amuvatinib is generally better tolerated than traditional chemotherapy, but because it blocks several kinases, it has a specific set of side effects.

Common Side Effects (>10%):

• Gastrointestinal Upset: Nausea, vomiting, and mild diarrhea.
• Fatigue: A general sense of tiredness.
• Skin Rash: Mild acne-like breakouts or dry skin.
• Anorexia: Loss of appetite.

Serious Adverse Events:

• Hepatotoxicity: Elevation of liver enzymes (ALT/AST), requiring dose delays.
• Myelosuppression: When used with chemotherapy, it can worsen the drop in white blood cell counts.
• Black Box Warning: There is currently no FDA Black Box Warning for amuvatinib.
• Management Strategies: Nausea is typically managed with standard antiemetics. Liver function is monitored every two weeks; if enzymes rise, the drug is held until they return to normal levels.

Research Areas

In the field of Stem Cell and Regenerative Medicine, amuvatinib is being studied for its effect on “Cancer Stem Cell Maintenance.” Researchers have found that proteins like AXL and c-Kit are vital for keeping cancer stem cells alive. By using amuvatinib to block these “stemness” signals, scientists hope to not only shrink the tumor but to “sterilize” the cancer stem cell niche. This regenerative approach aims to prevent the cancer from ever growing back, effectively helping the patient’s body return to a state of healthy tissue regeneration.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Baseline Liver Function Tests (LFTs): To ensure the liver can process the medication.
• Genetic Profiling: To check for c-Kit or PDGFR mutations.
• Complete Blood Count (CBC): To establish baseline immune cell levels.

Precautions During Treatment:

• Sun Protection: Like many kinase inhibitors, amuvatinib can make your skin more sensitive to UV light. Wear sunscreen and protective clothing.
• Avoid Grapefruit: Grapefruit juice can interfere with the enzymes that break down amuvatinib, leading to dangerously high levels of the drug in your blood.

“Do’s and Don’ts” List:

• DO take the medication with a meal to reduce the chance of nausea.
• DO report any yellowing of the eyes or skin (jaundice) to your doctor immediately.
• DON’T take any new herbal supplements (like St. John’s Wort) without asking your oncologist.
• DON’T skip doses; the drug needs to be in your system constantly to keep the cancer’s DNA repair systems “off.”

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Amuvatinib is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.